FDA Approves Supplemental Application for Epidiolex by Jazz Pharmaceuticals
The FDA has approved a supplemental application for Epidiolex, which contains cannabidiol as its active ingredient.
Therapeutic Area
Therapeutic area intelligence for Cannabinoids with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Curaleaf Laboratories is recalling three batches of Curaleaf Oil due to low THC content.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.